Medical Policy Updates

Home ❯ Providers ❯ Medical Policies and Coverage ❯ Back to Medical Policy Updates ❯ Notification of Drug Policy Revisions Effective January 1, 2023 (Posted October 17, 2022)

Notification of Drug Policy Revisions Effective January 1, 2023 (Posted October 17, 2022)

Policy Name Revised Criteria

Infliximab (Remicade®) and Infliximab Biosimilars “Notification”

Changed requirement for trial and failure of preferred agents to include two agents: Avsola and Inflectra. Adjusted non-preferred agents to include Remicade and Infliximab. Policy notification given 10/17/2022 for effective date 1/1/2023.